Neuropathic pain

Cancer Pain: Assessment and Management, Second Edition

Volumn , Issue , 2009, Pages 478-505

  Cruciani, Ricardo A ^a   Strada, E Alessandra ^a   Knotkova, Helena ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874976444     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511642357.027     Document Type: Chapter

References (155)

1. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82:263-74, 1999.
2. Cleeland CS, Gonin R, Hatfield R, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330: 592-6, 1994.
3. Grond S, Radbruch L, Meuser T, et al. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 79:15-20, 1999.
4. Anderson KO, Syrjala KL, Cleeland CS. How to assess cancer pain. In: Turk DC, Melzack R, eds. Handbook of pain assessment. New York, London: The Guilford Press, 2001, pp 579-600.
5. Katz N. Neuropathic pain in cancer and AIDS. Clin J Pain 16: S41-8.
6. Boucher TJ, Okuse K, Bennett DL, et al. Potent analgesic effects of GDNF in neuropathic pain states. Science 2000, 290:124.
7. Asbury AK, Fields HL. Pain due to peripheral nerve damage: a hypothesis. Neurology 34:1587-90, 1984.
8. Elliott KJ. Taxonomy and mechanisms of neuropathic pain. Semin Neurol 14:195-205, 1994.
9. Chen R, Cohen LG, Hallett M. Nervous system reorganization following injury. Neuroscience 111:761-73, 2002.
10. Empl M, Renaud S, Erne B, et al. TNF-alpha expression in painful and nonpainful neuropathies. Neurology 56:1371-7, 2001.
11. Dworkin RH, Backonja M, Rowbotham MC et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60:1524-34, 2003.
12. Jin SX, Zhuang ZY, Woolf CJ, et al. p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 23:4017-22, 2003.
13. Bennett GJ. Neuropathic pain. In: Wall PD, Melzack R, eds. Textbook of pain. Edinburgh: Churchill Livingstone, 1994, pp 201-24.
14. Elbert T, Flor H, Birbaumer N, et al. Extensive reorganization of the somatosensory cortex in adult humans after nervous system injury. Neuroreport 5:2593-7, 1994.
15. McGaraughty S, Wismer CT, Zhu CZ, et al. Effects of A- 317491, a novel and selective P2X3/P2X2/3 receptor antagonist, on neuropathic, inflammatory and chemogenic nociception following intrathecal and intraplantar administration. Br J Pharmacol 140:1381-8, 2003.
16. Vergnolle N, Bunnett NW, Sharkey KA, et al. Proteinase- activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med 7:821-6, 2001.
17. Knotkova H, Pappagallo M. Pharmacology of pain transmission and modulation. II. Peripheral mechanisms. In: Pap- pagallo M, ed. The neurological basis of pain. New York: McGraw-Hill, 2005, pp 53-60.
18. Ross RA, Coutts AA, McFarlane SM et al. Actions of cannabi- noid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40:221-32, 2001.
19. Piomelli D, Beltramo M, Giuffrida A, et al. Endogenous cannabinoid signaling. Neurobiol Dis 5:462-73, 1998.
20. Calignano A, La Rana G, Giuffrida A, et al. Control of pain initiation by endogenous cannabinoids. Nature 394:277-81, 1998.
21. Davis AJ, Perkins MN. Induction of B1 receptors in vivo in a model of persistent inflammatory mechanical hyperalgesia in the rat. Neuropharmacology 33:127-33, 1994.
22. Seabrook GR, Bowery BJ, Heavens R, et al. Expression of B1 and B2 bradykinin receptor mRNA and their functional roles in sympathetic ganglia and sensory dorsal root ganglia neurones from wild-type and B2 receptor knockout mice. Neuropharmacology 36:1009-17, 1997.
23. Gomes JA, Li X, Pan HL et al. Intrathecal adenosine interacts with a spinal noradrenergic system to produce antinociception in nerve-injured rats. Anesthesiology 91:1072-9, 1999.
24. Zhu CZ, Mikusa J, Chu KL etal. A-134974: a novel adenosine kinase inhibitor, relieves tactile allodynia via spinal sites of action in a peripheral nerve injured rats. Brain Res 905:10410, 2001.
25. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol 347:1-11, 1998.
26. Pappagallo M, Gaspardone A, Tomai F et al. Analgesic effect of bamiphylline on pain induced by intradermal injection of adenosine. Pain 53:199-204, 1993.
27. Khandwala H, Zhang Z, Loomis CW. Inhibition of strychnine- allodynia is mediated by spinal adenosine A1- but not A2- receptors in the rat. Brain Res 808:106-9, 1998.
28. Matthews EA, Dickenson AH. Effects of spinally delivered N- and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain 92:235-46, 2001.
29. Luger NM, Mach DB, Sevcik MA, et al. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage 29: S32-46, 2005.
30. Lerner UH. Neuropeptidergic regulation of bone resorption and bone formation. J Muskuloskelet Neuronal Interact 2: 440-7, 2002.
31. Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor- 1 is essential for inflammatory thermal hyperalgesia. Nature 405:183-7, 2000.
32. Black JA, Liu S, Tanaka M, et al. Changes in the expression of tetrodotoxin-sensitive sodium channels within dorsal root ganglia neurons in inflammatory pain. Pain 108:237-47, 2004.
33. Waxman SG, Dib-Hajj SD. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann Neurol 57:785-8, 2005.
34. Marais E, Klugbauer N, Hofmann F. Calcium channel al- pha(2)delta subunits - structure and gabapentin binding. Mol Pharmacol 59:1243-8, 2001.
35. Sutton KG, Martin DJ, Pinnock RD. Gabapentin inhibits high- threshold calcium channel currents in cultured rat dorsal horn ganglion neurones. Br J Pharmacol 135:257-65, 2002.
36. Lai J, Hunter JC, Porreca F. The role of voltage-gated sodium channels in neuropathic pain. Curr Opin Neurobiol 13:291-7, 2003.
37. Zhou XF, Deng YS, Xian CJ, et al. Neurotrophins from dorsal root ganglia trigger allodynia after spinal nerve injury in rats. Eur J Neurosci 12:100-5, 2000.
38. Schafers M, Svensson CI, Sommer C, et al. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 23:2517-25, 2003.
39. Jarvis MF, Burgard EC, McGaraughty S, et al. A-317491, a novel potent and selective non-nucleotide antagonist of P2X3, and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A 99:1717985, 2002.
40. Boureau F, Doubrere JF, Luu M. Study of verbal description in neuropathic pain. Pain 42:145-52, 1990.
41. Farrar JT, Portenoy RK. Neuropathic cancer pain: the role of adjuvant analgesics. Oncology (Williston Park) 15:1435-42, 2001.
42. Deshpande MA, Holden RR, Gilron I. The impact of therapy on quality of life and mood in neuropathic pain: what is the effect of pain reduction? Anesth Analg 102:1473-9, 2006.
43. Ivez R, Marsal C, Vidal J, et al. Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions. Eur J Pain 11:244-55, 2007.
44. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology 68:1178-82, 2007.
45. Closs SJ, Staples V, Reid I, et al. Managing the symptoms of neuropathic pain: an exploration of patients’ experiences. J Pain Symptom Manage 34:422-33, 2007.
46. Wallington M, Mendis S, Premawardhana U, et al. Local control and survival in spinal cord compression from lymphoma and myeloma. Radiother Oncol 42:43-7, 1997.
47. Correale J, Monteverde JA, Bueri JA, et al. Peripheral nervous system and spinal cord involvement in lymphoma. Acta Neurol Scand 83:45-51, 1991.
48. Vecht CJ. Cancer pain: a neurological perspective. Curr Opin Neurol 13:649-53, 2000.
49. Dimopoulos MA, Alexanian R. Waldenstrom’s macroglobu- linemia. Blood 83:1452-9, 1994.
50. Kissel JT, Mendell JR. Neuropathies associated with monoclonal gammopathies. Neuromuscul Disord 6:3-18, 1996.
51. Wicklund MP, Kissel JT. Paraproteinemic neuropathy. Curr Treat Options Neurol 3:147-56, 2001.
52. Portenoy RK. Cancer pain - epidemiology and syndromes. Cancer 63:2298-307, 1989.
53. Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 60:337-40, 2003.
54. Hammack JE, Michalak JC, Loprinzi CL, et al. Phase III evaluation of nortriptyline for alleviation of symptoms of cis- platinum-induced peripheral neuropathy. Pain 98:195-203, 2002.
55. Postma TJ, Hoekman K, van Riel JM, et al. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. J Neurooncol 45: 241-6, 1999.
56. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 249:9-17, 2002.
57. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 5(Suppl 1): S38-46, 2005.
58. Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29:387-92, 2004.
59. Posner JB. Side effects of chemotherapy. In: Posner JB, ed. Neurologic complications of cancer. Philadelphia: F. A. Davis Company, 1995, pp 282-310.
60. Krishnan AV, Goldstein D, Friedlander M, et al. Oxaliplatin- induced neurotoxicity and the development of neuropathy. Muscle Nerve 32:51-60, 2005.
61. Verstappen CC, Heimans JJ, Hoekman K, et al. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 63:1549-63, 2003.
62. Argyriou AA, Polychronopoulos P, Koutras A, et al. Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted? Support Care Cancer 13:647-651, 2005.
63. Postma TJ, Hoekman K, van Riel JM, et al. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. J Neurooncol 45: 241-6, 1999.
64. Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide- induced neuropathy. Neurology 59:1872-5, 2002.
65. Visovsky C. Chemotherapy-induced peripheral neuropathy. Cancer Invest 21:439-51, 2003.
66. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxali- platin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-61, 2004.
67. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 39:128-35, 2005.
68. Bove L, Picardo M, Maresca V, et al. A pilot study on the relation between cisplatin neuropathy and vitamin E. J Exp Clin Cancer Res. 20:277-80, 2001.
69. Argyriou AA, Chroni E, Koutras A, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64:26-31, 2005.
70. Durand JP, Alexandre J, Guillevin L, et al. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 16:587-91, 2005.
71. Birbaumer N, Lutzenberg W, Montoya P, et al. Effects of regional anesthesia on phantom limb pain are mirrored in changes in cortical reorganization. J Neurosci 17:5503-8, 1997.
72. Flor H, Elbert T, Knecht S, et al. Phantom limb pain as a perceptual correlate of massive cortical reorganization following arm amputation. Nature 375:482-4, 1995.
73. Karl A, Birbaumer N, Lutzenberger W, et al. Reorganization of motor and somatosensory cortex in upper extremity amputees with phantom limb pain. J Neurosci 21:3609-18, 2001.
74. Kew JJ, Ridding MC, Rothwell JC, et al. Reorganization of cortical blood flow and transcranial magnetic stimulation maps in human subjects after upper limb amputation. J Neurophysiol 72:2517-24, 1994.
75. Pascual-Leone A, Peris M, Tormos JM, et al. Reorganization of human cortical motor output maps following traumatic forearm amputation. Neuroreport 7:2068-70, 1996.
76. Sherman RA, Arena JG. Phantom limb pain: mechanisms, incidence and treatment. Clin Rev Phys Rehabil Med 4:1-26, 1992.
77. Jeannerod M. The representing brain: neural correlates of motor intention and imagery. Brain Behav Sci 17:187-245, 1994.
78. Jeannerod M. Mental imagery in the motor context. Neuropsy- chologia 33:1419-32, 1995.
79. Lotze M, Grodd W, Birbaumer N, et al. Does the use of a myoelectric prosthesis prevent cortical reorganization and phantom limb pain? Nat Neurosci 2:501-2, 1999.
80. Lotze M, Flor H, Grodd W, et al. Phantom movements and pain. An fMRI study in upper limb amputees. Brain 124:226-877, 2001.
81. Pezzin LE, Dillingham TR, MacKenzie EJ. Rehabilitation and the long-term outcomes of persons with trauma-related amputations. Arch Phys Med Rehabil 81:292-300, 2000.
82. Johnson R. Herpes zoster - predicting and minimizing the impact of post-herpetic neuralgia. J Antimicrob Chemother Suppl T1:1-8, 2001.
83. Haanpaa M, Laippala P, Nurmikko T. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia. J Pain Symptom Manage. 20:50-8, 2000.
84. Tremonts-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 60:1029-52, 2000.
85. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280:1831-6, 1998.
86. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280:1837-42, 1998.
87. Caraceni A, Zecca E, Martini C, et al. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 17:441-5, 1999.
88. Bosnjak S, Jelic S, Susnjar S, et al. Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study. J Chemother 14:214-19, 2002.
89. Twycross R, Wilcock A: Palliative care formulary, v2.0 CD- ROM. 2002. Palliativedrugs.com.
90. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 352:1324-34, 2005.
91. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 6:253-60, 2005.
92. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of prega- balin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 115:254-63, 2005.
93. Hadj Tahar A. Pregabalin for peripheral neuropathic pain. Issues Emerg Health Technol March:1-4, 2005.
94. Freynhagen R, Grond S, Hagebeuker A, et al. Efficacy and safety of pregabalin in treatment of refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract 61:1989-96, 2007.
95. Brodie MJ. Lamotrigine. Lancet 339:1397-400, 1992.
96. Guay DR. Oxcarbazepine, topiramate, zonisamide, and lev- etiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother 1:18-37, 2003.
97. Nakamura-Craig M, Follenfant RL. Effect of lamotrigine in the effect of acute and chronic hyperalgesia induced by PGE2 and in the chronic hyperalgesia in rats with streptozotocin- induced diabetes. Pain 63:33-7, 1995.
98. Canavero S, Bonicalzi V. Lamotrigine control of central pain. Pain 68:179-81, 1996.
99. Vestergaard K, Andersen G, Gottrup H, et al. Lamotrigine for central poststroke pain: a randomized controlled trial. Neurology 56:184-90, 2001.
100. Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 64:1134-8, 2005.
101. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain 128:168-79, 2007.
102. Silver M, Blum D, Grainger J, et al. Double blind, placebo- controlled trial of lamotrigine in combination with other medication for neuropathic pain. J Pain Symptom Manage 34:44654, 2007.
103. Breuer B, Pappagallo M, Knotkova H, et al. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther 29:2022-30, 2007.
104. Sobotka JL, Alexander B, Cook BL. A review of carba- mazepine’s hematologic reactions and monitoring recommendations. DICP 24:1214-19, 1990.
105. Portenoy RK, Khan E, Layman M, et al. Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology 41:1457-61, 1991.
106. Jadad AR. The WHO anelgesic ladder for cancer pain management: stepping up the quality of its evaluation. JAMA 274, 1870-73, 1995.
107. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251:85-7, 1991.
108. Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA 260:3025-9, 1988.
109. Nyswander M, Dole VP. The present status of methadone blockade treatment. Am J Psychiatry 123:1441-2, 1967.
110. Krantz MJ, Kutinsky IB, Robertson AD, et al. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 23:802-5, 2003.
111. Cruciani RA, Sekine R, Homel P, et al. Measurements of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage 29:385-91, 2005.
112. Kornick CA, Kilborn MJ, Santiago-Palma J, et al. QTc interval prolongation associated with intravenous methadone. Pain 105:499-506, 2003.
113. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer 86:1856-66, 1999.
114. Mercadante S, Cacuccio A, Fulfaro F, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19:2898904, 2001.
115. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326:1250-6, 1992.
116. Watson CP, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 51:1166, 1998.
117. Morello CM, Lechband SG, Stoner CP, et al. Randomized double blind study comparing the efficacy of gabapentin with amitriptyline in diabetic peripheral neuropathy pain. Arch Intern Med 59:1931-7, 1999.
118. Kalso E, Tasmuth T, Neuvonen P. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 64:293-302, 1996.
119. Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv Rev Psychiatry 7:257-77, 2000.
120. Sindrup SH, Grodum E, Gram LF, et al. Concentration- response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study. Ther Drug Monit 13:408-14, 1991.
121. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 57:1583-8, 2001.
122. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 116:109-18, 2005.
123. Raskin J, Pritchett YL, Wang F, et al. A double blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 6:346-56, 2005.
124. Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 67:1411-20, 2006.
125. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo controlled study. Pain 110:697706, 2004.
126. Mao J, Chen LL. Systemic lidocaine for neuropathic pain relief. Pain 87:7-17, 2000.
127. Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexile- tine: a prospective study. J Pain Symptom Manage 12:161-7, 1996.
128. Chong SF, Bretscher ME, Mailliard JA, et al. Pilot study evaluating local anesthetics administered systemically for treatment of pain in patients with advanced cancer. J Pain Symptom Manage 13:112-17, 1997.
129. Bennett G, Serafini M, Burchiel K, et al. Evidence-based review of the literature on intrathecal delivery of pain medication. J Pain Symptom Manage 20: S12-36, 2000.
130. Du Pen SL, Kharash ED, Williams A, et al. Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain 49:293-300, 1992.
131. Slonimski M, Abram SE, Zuniga RE. Intrathecal baclofen in pain management. Reg Anesth Pain Med 29:269-76, 2004.
132. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methyl- prednisolone for intractable postherpetic neuralgia. N Engl J Med 343:1514-19, 2000.
133. Pierce TL, Tiong GK, Olley JE. Morphine and methadone dependence in the rat: withdrawal and brain metenkephalin levels. Pharmacol Biochem Behav 42:91-6, 1992.
134. Kannan TR, Saxena A, Bhatnagar S, et al. Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J Pain Symptom Manage 23:60-5, 2002.
135. Kiefer RT, Rohr P, Ploppa A, et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open label phase II study. Pain Med 9:1173-201, 2008.
136. Koffler SP, Hampstead BM, Irani F, et al. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neu- ropsychol 22:719-29, 2007.
137. Cvrcek P. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med 9:253-7, 2008.
138. Fromm GH. Baclofen as an adjuvant analgesic. J Pain Symptom Manage 9:500-9, 1994.
139. Fernandez F, Adams F, Holmes VF. Analgesic effect of alprazolam in patients with chronic, organic pain of malignant origin. J Clin Psychopharmacol 7:167-9, 1987.
140. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev CD003474, 2005.
141. Terpos E, Dimopoulos MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 16:1223-31, 2005.
142. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1:45-52, 2003.
143. Kovcin V, Jelic S, Babovic N, Tomasevic Z. A pilot study to assess the efficacy of salmon calcitonin in the relief of neuropathic pain caused by extraskeletal metastases. Support Care Cancer 2:71-3, 1994.
144. Vecht CJ, Haaxma-Reiche H, van Putten WL, et al. Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology 39:1255-7, 1989.
145. Watanabe S, BrueraE. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 9:442-5, 1994.
146. Khojainova N, Santiago-Palma J, Kornick C, et al. Olanzapine in the management of cancer pain. J Pain Symptom Manage 23:346-50, 2002.
147. Hohmann AG. Spinal and peripheral mechanisms of cannabi- noid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 121:173-90, 2002.
148. Goya P, Jagerovic N, Hernandez-Folgado L, et al. Cannabi- noids and neuropathic pain. Mini Rev Med Chem 3:765-72, 2003.
149. Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 61:14960, 2004.
150. Hoffman AG. Spinal and peripheral mechanisms of cannabi- noid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 121:173-90, 2002.
151. Karst M, Salim K, Burstein S. Analgesic affect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290:1757-62, 2003.
152. Nurmikko T., Serpell MG, Hoggart B, et al. Sativex successfully treats neuropathic pain characterized by allodynia: a randomized, double-blind, placebo-controlled clinical trial. Pain 133:210-20, 2007.
153. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 80:533-8, 1999.
154. White WT, Patel N, Drass M, et al. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med. (4):321-30, 2003.
155. Ellison N, Loprinzi CL, Kugler J, et al. Phase III placebo- controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients. J Clin Oncol 15:2974-80, 1997.